Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study

Brentuximab vedotin (BV) is an antibody-drug conjugate targeting the CD30 antigen which is highly expressed on Reed–Sternberg cells or Hodgkin cells of classical Hodgkin lymphoma (cHL) and systemic...